These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 10540345)

  • 1. A MAGE-A4 peptide presented by HLA-A2 is recognized by cytolytic T lymphocytes.
    Duffour MT; Chaux P; Lurquin C; Cornelis G; Boon T; van der Bruggen P
    Eur J Immunol; 1999 Oct; 29(10):3329-37. PubMed ID: 10540345
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of five MAGE-A1 epitopes recognized by cytolytic T lymphocytes obtained by in vitro stimulation with dendritic cells transduced with MAGE-A1.
    Chaux P; Luiten R; Demotte N; Vantomme V; Stroobant V; Traversari C; Russo V; Schultz E; Cornelis GR; Boon T; van der Bruggen P
    J Immunol; 1999 Sep; 163(5):2928-36. PubMed ID: 10453041
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Generation of CTL recognizing an HLA-A*0201-restricted epitope shared by MAGE-A1, -A2, -A3, -A4, -A6, -A10, and -A12 tumor antigens: implication in a broad-spectrum tumor immunotherapy.
    Graff-Dubois S; Faure O; Gross DA; Alves P; Scardino A; Chouaib S; Lemonnier FA; Kosmatopoulos K
    J Immunol; 2002 Jul; 169(1):575-80. PubMed ID: 12077290
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of MAGE-3-specific cytolytic T lymphocytes in human leukocyte antigen-A2 melanoma patients.
    Valmori D; Liénard D; Waanders G; Rimoldi D; Cerottini JC; Romero P
    Cancer Res; 1997 Feb; 57(4):735-41. PubMed ID: 9044853
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A peptide encoded by human gene MAGE-3 and presented by HLA-A2 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE-3.
    van der Bruggen P; Bastin J; Gajewski T; Coulie PG; Boël P; De Smet C; Traversari C; Townsend A; Boon T
    Eur J Immunol; 1994 Dec; 24(12):3038-43. PubMed ID: 7805731
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Overlapping peptides of melanocyte differentiation antigen Melan-A/MART-1 recognized by autologous cytolytic T lymphocytes in association with HLA-B45.1 and HLA-A2.1.
    Schneider J; Brichard V; Boon T; Meyer zum Büschenfelde KH; Wölfel T
    Int J Cancer; 1998 Jan; 75(3):451-8. PubMed ID: 9455808
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A MAGE-A1 peptide is recognized on HLA-B7 human tumors by cytolytic T lymphocytes.
    Luiten R; van der Bruggen P
    Tissue Antigens; 2000 Feb; 55(2):149-52. PubMed ID: 10746786
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cytolytic T lymphocytes recognize an antigen encoded by MAGE-A10 on a human melanoma.
    Huang LQ; Brasseur F; Serrano A; De Plaen E; van der Bruggen P; Boon T; Van Pel A
    J Immunol; 1999 Jun; 162(11):6849-54. PubMed ID: 10352307
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A MAGE-A4 peptide presented by HLA-B37 is recognized on human tumors by cytolytic T lymphocytes.
    Zhang Y; Stroobant V; Russo V; Boon T; van der Bruggen P
    Tissue Antigens; 2002 Nov; 60(5):365-71. PubMed ID: 12492812
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cancer/testis antigen expression and specific cytotoxic T lymphocyte responses in non small cell lung cancer.
    Groeper C; Gambazzi F; Zajac P; Bubendorf L; Adamina M; Rosenthal R; Zerkowski HR; Heberer M; Spagnoli GC
    Int J Cancer; 2007 Jan; 120(2):337-43. PubMed ID: 17066423
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of two novel HLA-A*0201-restricted CTL epitopes derived from MAGE-A4.
    Jia ZC; Ni B; Huang ZM; Tian Y; Tang J; Wang JX; Fu XL; Wu YZ
    Clin Dev Immunol; 2010; 2010():567594. PubMed ID: 21350607
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of new antigenic peptide presented by HLA-Cw7 and encoded by several MAGE genes using dendritic cells transduced with lentiviruses.
    Breckpot K; Heirman C; De Greef C; van der Bruggen P; Thielemans K
    J Immunol; 2004 Feb; 172(4):2232-7. PubMed ID: 14764691
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of MAGE-3 derived synthetic peptide as a human lung cancer antigen recognized by cytotoxic T lymphocytes.
    Eifuku R; Takenoyama M; Yoshino I; Imahayashi S; So T; Yasuda M; Sugaya M; Yasumoto K
    Int J Clin Oncol; 2001 Feb; 6(1):34-9. PubMed ID: 11706525
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A MAGE-A3 peptide presented by HLA-DP4 is recognized on tumor cells by CD4+ cytolytic T lymphocytes.
    Schultz ES; Lethé B; Cambiaso CL; Van Snick J; Chaux P; Corthals J; Heirman C; Thielemans K; Boon T; van der Bruggen P
    Cancer Res; 2000 Nov; 60(22):6272-5. PubMed ID: 11103782
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The production of a new MAGE-3 peptide presented to cytolytic T lymphocytes by HLA-B40 requires the immunoproteasome.
    Schultz ES; Chapiro J; Lurquin C; Claverol S; Burlet-Schiltz O; Warnier G; Russo V; Morel S; Lévy F; Boon T; Van den Eynde BJ; van der Bruggen P
    J Exp Med; 2002 Feb; 195(4):391-9. PubMed ID: 11854353
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A newly identified MAGE-3-derived epitope recognized by HLA-A24-restricted cytotoxic T lymphocytes.
    Oiso M; Eura M; Katsura F; Takiguchi M; Sobao Y; Masuyama K; Nakashima M; Itoh K; Ishikawa T
    Int J Cancer; 1999 May; 81(3):387-94. PubMed ID: 10209953
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Variable expression on lung cancer cell lines of HLA-A2-binding MAGE-3 peptide recognized by cytotoxic T lymphocytes.
    Takaki T; Hiraki A; Uenaka A; Gomi S; Itoh K; Udono H; Shibuya A; Tsuji T; Sekiguchi S; Nakayama E
    Int J Oncol; 1998 May; 12(5):1103-9. PubMed ID: 9538136
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of a new MAGE-A10 antigenic peptide presented by HLA-A*0201 on tumor cells.
    Jia ZC; Tian Y; Huang ZM; Wang JX; Fu XL; Ni B; Wu YZ
    Cancer Biol Ther; 2011 Feb; 11(4):395-400. PubMed ID: 21124073
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of a CD8 co-receptor independent T-cell receptor specific for tumor-associated antigen MAGE-A4 for next generation T-cell-based immunotherapy.
    Davari K; Holland T; Prassmayer L; Longinotti G; Ganley KP; Pechilis LJ; Diaconu I; Nambiar PR; Magee MS; Schendel DJ; Sommermeyer D; Ellinger C
    J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33771892
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Heterogeneous T-cell response to MAGE-A10(254-262): high avidity-specific cytolytic T lymphocytes show superior antitumor activity.
    Dutoit V; Rubio-Godoy V; Dietrich PY; Quiqueres AL; Schnuriger V; Rimoldi D; Liénard D; Speiser D; Guillaume P; Batard P; Cerottini JC; Romero P; Valmori D
    Cancer Res; 2001 Aug; 61(15):5850-6. PubMed ID: 11479225
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.